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Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite the use of
optimized first-line therapy, GBM is still associated with a poor prognosis and an effective second-line therapy
remains an important challenge in this patient population. In 2009, the US Food and Drug Administration (FDA)
approved the monoclonal anti-VEGF-antibody bevacizumab for the treatment of relapsed GBM after two phase-II
studies showed its efficacy and safety, alone or in combination with irinotecan, in relapsed GBM. In contrast, the
European Medicines Agency (EMA) concluded from the same published data that a clear benefit in terms of overall
survival was not shown and subsequently did not grant approval for bevacizumab in this setting. Here, we report
on a 53-year old patient with relapsed GBM who was treated with bevacizumab as single agent. After three months,
the tumor volume was reduced and the Karnofsky performance status was substantially improved compared to the
baseline at the time of relapse. After continued long-term treatment for 26 months, the patient remains in an excellent
general condition. Moreover, the measurement of the tumor volume using multiple imaging modalities shows a
sustained treatment response. In conclusion, this case supports the notion that individual patients respond
exceptionally well to treatment with anti-VEGF therapy and suggests that future trials are needed to better identify
the patient population that responds to bevacizumab.
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Glioblastoma multiforme (GBM) is the most common
malignant primary brain tumor in adults and the 5-year
survival rate is <5% in adults [1,2]. According to the guide-
lines of the National Guideline Clearinghouse of the U.S.
Department of Health & Human Services, the recom-
mended therapy for a newly diagnosed GBM is surgical
debulking provided that unacceptable neurologic deficit
can be avoided, followed by adjuvant radiotherapy [3,4].
Concomitant radiotherapy and temozolomide followed by
adjuvant temozolomide for 6 courses have been shown
to significantly prolong overall survival (OS) compared
to radiotherapy alone [5,6]. The median OS in patients
treated with additional temozolomide is prolonged from* Correspondence: katrin.schweneker@lrz.tum.de; philipp.jost@lrz.tum.de
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unless otherwise stated.12.1 months to 14.6 months when compared to radiother-
apy alone. In addition, the 2-year survival is improved from
10.4% with radiotherapy alone to 26.5% with radiotherapy
and temozolomide [6]. Due to their invasive growth pat-
tern, GBM have a high relapse rate [7]. According to the
guidelines of the National Comprehensive Cancer Network
(NCCN), the recommended therapy for a resectable locally
relapsed GBM is resection with or without implantation of
a carmustine wafer. However, there is no clearly defined
standard therapy for relapsed unresectable GBM [8,9]. In
this case, the treatment decision depends on multiple pa-
rameters such as prior therapy, time to relapse, tumor
grade, and performance status [8,9]. Treatment options in-
clude repeated surgery, radiation, or chemotherapy [10].
Chemotherapeutic regimes include either monotherapy
with lomustine (CCNU), platinum compounds, or temo-
zolomide [9,11,12]. Alternatively, medically fit and healthy
patients can be treated with polychemotherapy usingntral. This is an Open Access article distributed under the terms of the Creative
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[13]. Two uncontrolled phase II studies showed that
the monoclonal human anti-VEGF-antibody bevacizu-
mab, alone or in combination with irinotecan, prolongs
progression-free survival (PFS) and overall survival
(OS) in patients with relapsed GBM compared to his-
torical data [14,15]. Based on this data, bevacizumab
was approved by the US Food and Drug administration
(FDA) for use in relapsed GBM. However, it is currently
not approved by the European Medicines Agency (EMA)
for relapsed GBM because of missing evidence that bevaci-
zumab prolongs survival. In 2013, Johnson et al. published
a population-based analysis in which they compared pa-
tients in the United States who eventually succumbed to
GBM in 2006, 2008, and 2010 [16]. The difference in sur-
vival between 2008 and 2010 was significantly better for
patients treated with bevacizumab [16]. This circumstantial
evidence suggests that the improved median survival of
GBM patients in the US might be due to the approval and
use of bevacizumab, however a direct comparison of sub-
populations is missing so far. Here we report on the suc-
cessful long-term treatment of a relapsed GBM patient
with bevacizumab as monotherapy for the last 26 months
with an ongoing improvement in tumor volume and qual-
ity of life.Figure 1 Relapse of GBM after resection and radiochemotherapy. A N
B Gadolinium-enhanced T1-weighted MRI shows strong peripheral and irre
pronounced surrounding edema and mass effect. D In the PET/CT scan an
corresponds with focal increased 18 F-FET uptake exhibiting Tu/Bg ratio ofCase report
In November 2011, a 53-year-old male patient presented
to our clinics for chemoradiotherapy after resection of a
cerebral lesion that was diagnosed as GBM WHO IV° by
histopathology. An epigenetic silencing of O6-methylgua-
nine-DNA methyltransferase (MGMT) by promoter
methylation was not detected by real-time PCR of tumor
DNA. Approximately six weeks after resection, the patient
was started on standard combined chemotherapy and ra-
diation (temozolomide 75 mg/m2/day and involved-field
radiation at a total dose of 60 Gy in 2.0 Gy fractions over a
6-week period). The radiotherapy was well tolerated and
the treatment with temozolomide was continued with
150 mg/m2 d1-5 in the first cycle followed by 200 mg/m2
d1-5 every 4 weeks. In April 2012, after three courses of
temozolomide, the patient presented with intermittent dis-
orientation and a worsened general condition. The native
and Gadolinium-enhanced T1-weighted cerebral magnetic
resonance imaging (cMRI) showed a tumor involving the
right basal ganglia with strong peripheral and irregular
contrast enhancement (Figure 1A and B). In the T2-
weighted FLAIR a pronounced surrounding edema and
mass effect was seen in the area of the basal ganglia
(Figure 1C). Because of the clinical symptoms, the deterio-
rated general condition, and the unmethylated MGMTative T1-weighted MRI shows a tumor involving the right basal ganglia.
gular enhancement of the tumor. C T2-weighted FLAIR demonstrates
d E the fusion of PET and MRI, the lesion described in the MRI
2.4.
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interpreted as GBM relapse. A radiotherapy-induced pseu-
doprogression is not considered to cause the radiographic
findings. To confirm this we performed 18 F-fluoroethyl-
tyrosine-positron emission tomography/computer tomo-
graphy (FET-PET/CT) scan (Figure 1D and E). The PET/
CT (Figure 1D) showed a focally increased 18 F-FET up-
take corresponding to the contrast enhancement de-
scribed in cMRI, which was emphasized in the fusion of
PET and MRI (Figure 1E). The mean tumoral uptake (Tu)
was evaluated and the ratio to background (Bg) was calcu-
lated with Tu/Bg ratio of 2.4. This value exceeds the
threshold of 1.6 thereby indicating an active malignancy
[18]. Because of the localization of the relapsed GBM and
the reduced general performance status, resection was
deemed impossible. It was decided to treat the patient
with anti-VEGF antibody (bevacizumab) monotherapy
(Avastin®) in an off-label setting. Bevacizumab was given
at a dose of 10 mg/kg body weight on d1 and d15 every
four weeks. Concurrently, the palliative care team was in-
volved in patient’s care because of the poor general per-
formance status. After three courses, a reduction in tumor
size from 51 × 21 × 25 mm to 39 × 17 × 17 mm was ob-
served at Gadolinium-enhanced T1-weighted cMRI, and
the degree of contrast enhancement within the tumor had
decreased (Figure 2). On day one of the forth course ofFigure 2 GBM after three courses of bevacizumab. Gadolinium-
enhanced T1-weighted MRI shows a reduction in tumor size as well
as decreasing and discontinuous tumor enhancement.bevacizumab, our patient presented with dyspnoe at the
emergency room and the suspected diagnosis of pulmo-
nary embolism was confirmed by CT scan. Therapeutic
anticoagulation was started using low molecular weight
heparin. Bevacizumab was continued one week later at the
initially used dosing regimen. Under low molecular weight
heparin, there were no further thromboembolic events or
other bevacizumab-related serious adverse reactions until
to date. During ongoing therapy with bevacizumab, the
patient’s Karnofsky performance status improved steadily
from 50% at the beginning of treatment with bevacizumab
to 80% after 6 months and the palliative care team stopped
patient’s care. Concomitant corticosteroid therapy was re-
duced continuously and finally stopped. The last cMRI
performed after 17 courses of bevacizumab showed a very
good partial response to bevacizumab therapy with a
tumor size of 35 × 15 × 15 mm in the unenhanced T1-
weighted sequences (Figure 3A) and a lack of contrast en-
hancement in the lateral portions of the tumor in the
Gadolinium-enhanced T1-weighted sequences (Figure 3B).
T2-weighted FLAIR demonstrated a significant decrease
of peritumoral edema (Figure 3C). A very low level of 18 F-
FET tracer uptake was noted (Figure 4), which was sub-
stantially lower than the tracer uptake observed before
treatment (Figure 1D and E). Moreover, Tu/Bg ratio in the
post treatment PET/CT scan was 1.3 consistent with re-
active changes after treatment (Figure 4). After the excel-
lent treatment response observed under bevacizumab
treatment, we evaluated to stop monotherapy with bevaci-
zumab. However, since remaining active tumor cannot be
fully excluded by the imaging modalities used, we decided
together with the interdisciplinary tumor board to further
extend the treatment.
26 months after the diagnosis of relapsed GBM, our
patient remains in an excellent general condition with a
Karnofsky performance status of 100% without further
adverse side effects to the current therapy. Under on-
going treatment with bevacizumab the patient is able to
live a self-reliant, socially active life.
Discussion
Despite therapeutic advances, the prognosis for patients
with GBM is still poor [19]. Nevertheless, a small frac-
tion of patients with GBM (3–5%) survive longer that
36 months and they are referred to as long-term survi-
vors [2]. Young age, female gender, higher preoperative
Karnofsky performance status, unilateral tumor, gross total
resection, and adjuvant radiochemotherapy are associated
with prolonged survival [20]. Furthermore, there are some
molecular markers, e.g. p53 mutation, MGMT promoter
methylation, or isocitrate dehydrogenase 1 (IDH1) mu-
tations that are frequently found in long-term survivors
[20]. Single amino acid mutations in IDH1 can lead to
the loss of regular enzyme function [21]. The mutated
Figure 3 Treatment response after 17 courses of bevacizumab in cMRI. A Non-enhanced T1-weighted MRI reveals further decrease in lesion
size. Hyperintense hemorrhagic changes are present within the medial portion of the tumor. B Gadolinium-enhanced T1-weighted MRI documents lack
of contrast enhancement in the lateral portions of the tumor. Only a slight enhancement in addition to the hyperintense hemorrhagic changes in the
medial portion of the tumor was observed. C T2-weighted FLAIR demonstrates a decrease of peritumoral edema.
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hydroxyglutarate (2-HG), which causes genome-wide
epigenetic changes in human gliomas [22]. Patients har-
boring mutated IDH1 and corresponding epigenetic
changes have a better prognosis than patients diagnosed
with GBM with wild-type IDH1 [21,23]. This is exem-
plified by the fact that treatment with bevacizumab as
single agent in patients with relapsed GBM and IDH1
mutation results in a significant better PFS and OS
compared to patients without IDH1 mutation (PFS 3.23
vs. 1.37 months, p = 0.05; and OS 10.16 vs. 4.90 months,
p = 0.09) [24].
The MGMT promoter methylation is known to play
an important role in the cellular response to alkylating
agents such as temozolomide [5,25]. Significantly more
long-term survivors harbor MGMT promoter methyla-
tion compared to patients that survive shorter than
18 months [20]. Furthermore, Capdevila and colleagues
showed, that patients with methylated MGMT promoterstatus derive greater benefit from neoadjuvant temozo-
lomide treatment than those without methylated
MGMT promoter status [26]. Concerning bevacizumab,
a previously published single-arm study showed that pa-
tients with a relapsed GBM treated with the combination
of bevacizumab and fotemustin had an improved PFS
when the MGMT promoter was methylated [27], however
the difference to historical controls was not statistically
significant. An alternative single-arm study used bevacizu-
mab in combination with temozolomide after radiotherapy
in newly diagnosed GBM patients [28]. In this study, pa-
tients with MGMT promoter methylation had an im-
proved median OS and PFS compared to patients without
MGMT promoter methylation [28]. The patients of the
MGMT unmethylated group appeared to have a poor out-
come, possibly caused by the reduced effectiveness of
temozolomide.
Since the approval of bevacizumab for relapsed GBM
by the FDA, there is an ongoing attempt to improve the
Figure 4 Treatment response after 17 courses of bevacizumab in 18 F-FET-PET/CT and fusion of PET with MRI. A The native and B the
contrast-enhanced T1 cMRT scans show a decrease of the lesion initially described. C In the PET/CT and D the fusion of PET and MRI, the 18 F-FET
uptake is slightly diffuse increased with Tu/Bg uptake ration of 1.3 consitent with reactive changes after treatment and arguing against vital
tumor tissue.
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therapies. Several studies have analyzed the combination
of bevacizumab with various chemotherapeutic agents
that are recommended as second-line therapy for re-
lapsed unresectable GBM. In these studies, bevacizumab
was combined with irinotecan [14,29,30], oral etoposide
[31], temozolomide [32], carboplatin and etoposide [33],
or carboplatin and irinotecan [34]. All these combin-
ation therapies were effective treatments for relapsed
GBM, but did not improve the outcome over the level
observed with bevacizumab alone.
The presented case shows that monotherapy with be-
vacizumab can substantially prolong survival and improve
quality of life in patients with relapsed GBM. This ar-
gues that a better understanding of the clinical or mo-
lecular parameters that define the patient population
that will profit from bevacizumab monotherapy is ur-
gently needed. At this point, it is not clear whether a
definite correlation exists between improved PFS andOS in patients treated with bevacizumab as monother-
apy and their MGMT methylation status. The patient’s
current survival time of 26 months from start of mono-
therapy with bevacizumab after relapsed GBM exceeds
all expectations and surpasses to our knowledge survival
rates of other studies or reports. The patient remains in
an excellent general condition under ongoing treatment
with bevacizumab. At this point, we have no explanation
for this successful course, particularly taking into consid-
eration the reduced Karnofsky performance status of 50%
at time of relapse, male gender and unmethylated MGMT
promoter as negative prognostic survival markers. There-
fore, additional clinical trials and an improved molecular
characterization of these cases might help to identify pa-
tient populations that will likely benefit from an anti-
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